2020
DOI: 10.3390/jpm10040167 View full text |Buy / Rent full text
|
|

Abstract: The heterogeneity of colon cancers and their reactions presents both a challenge and promise for personalized medicine. The challenge is to develop effective biologically personalized therapeutics guided by predictive and prognostic biomarkers. Presently, there are several classes of candidate biomarkers, including genomic probes, inhibitory RNAs, assays for immunity dysfunction and, not to be forgotten, specific histopathologic and histochemical features. To develop effective therapeutics, candidate biomarker… Show more

Help me understand this report

Search citation statements

Order By: Relevance
Select...
0
0
0

Publication Types

Select...

Relationship

0
0

Authors

Journals